Acetylation: A lysine modification with neuroprotective effects in ischemic retinal degeneration

Experimental Eye Research

Volumn 127, Issue , 2014, Pages 124-131

  Alsarraf, Oday ^a   Fan, Jie ^a   Dahrouj, Mohammad ^a   Chou, C James ^a   Menick, Donald R ^a   Crosson, Craig E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Acetylation; HDAC; Ischemia; Neuroprotection; Retina

Indexed keywords

CASPASE 3; HISTONE DEACETYLASE; HISTONE H3; LYSINE; TRICHOSTATIN A; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ELECTRORETINOGRAPHY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HISTONE ACETYLATION; IMMUNOHISTOCHEMISTRY; MALE; MORPHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA CELL; RETINA DEGENERATION; RETINA ISCHEMIA; SYSTEMIC THERAPY; ADULT; ANIMAL CELL; ANIMAL TISSUE; CELL FUNCTION; CELL SURVIVAL; DRUG EFFECT; ENZYME INHIBITION;

ACETYLATION; HDAC; ISCHEMIA; NEUROPROTECTION; RETINA;

ACETYLATION; ANIMALS; BLOTTING, WESTERN; CASPASE 3; CELL SURVIVAL; ELECTRORETINOGRAPHY; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HYDROXAMIC ACIDS; LYSINE; MALE; NEUROPROTECTIVE AGENTS; RATS, INBRED BN; REPERFUSION INJURY; RETINAL DEGENERATION; RETINAL NEURONS; VALPROIC ACID;

EID: 84905375280     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2014.07.012     Document Type: Article

References (33)

1. Agudo M., Perez-Marin M.C., et al. Time course profiling of the retinal transcriptome after optic nerve transection and optic nerve crush. Mol. Vis. 2008, 14:1050-1063.
2. Boutillier A.L., Trinh E., et al. Constitutive repression of E2F1 transcriptional activity through HDAC proteins is essential for neuronal survival. Ann. N.Y. Acad. Sci. 2002, 973:438-442.
3. Chandrasekaran S., Peterson R.E., et al. Histone deacetylases facilitate sodium/calcium exchanger up-regulation in adult cardiomyocytes. FASEB J. 2009, 23(11):3851-3864.
4. Chen B., Cepko C.L. Requirement of histone deacetylase activity for the expression of critical photoreceptor genes. BMC Dev. Biol. 2007, 7:78.
5. Cor A., Pizem J., et al. Immunohistochemical analysis of pro- and active-caspase 3 in laryngeal squamous cell carcinoma. Virchows Arch. 2004, 444(5):439-446.
6. Crosson C.E., Mani S.K., et al. Inhibition of histone deacetylase protects the retina from ischemic injury. Investig. Ophthalmol. Vis. Sci. 2010, 51(7):3639-3645.
7. Dou H., Birusingh K., et al. Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J.Neurosci. 2003, 23(27):9162-9170.
8. Fleiss B., Nilsson M.K., et al. Neuroprotection by the histone deacetylase inhibitor trichostatin A in a model of lipopolysaccharide-sensitised neonatal hypoxic-ischaemic brain injury. J.Neuroinflamm. 2012, 9:70.
9. Haberland M., Montgomery R.L., et al. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 2009, 10(1):32-42.
10. Hao Y., Creson T., et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J.Neurosci. 2004, 24(29):6590-6599.
11. Huang L. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J.Cell. Physiol. 2006, 209(3):611-616.
12. Kanai H., Sawa A., et al. Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons. Pharmacogenomics J. 2004, 4(5):336-344.
13. Kim H.J., Rowe M., et al. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J.Pharmacol. Exp. Ther. 2007, 321(3):892-901.
14. Kim J., Sif S., et al. Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. Immunity 1999, 10(3):345-355.
15. Luo J., Su F., et al. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000, 408(6810):377-381.
16. Majumdar G., Adris P., et al. Pan-histone deacetylase inhibitors regulate signaling pathways involved in proliferative and pro-inflammatory mechanisms in H9c2 cells. BMC Genomics 2012, 13:709.
17. McKinsey T.A., Olson E.N. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J.Clin. Investig. 2005, 115(3):538-546.
18. New M., Olzscha H., et al. HDAC inhibitor-based therapies: can we interpret the code?. Mol. Oncol. 2012, 6(6):637-656.
19. Petri S., Kiaei M., et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2006, 22(1):40-49.
20. Phiel C.J., Zhang F., et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J.Biol. Chem. 2001, 276(39):36734-36741.
21. Produit-Zengaffinen N., Pournaras C.J., et al. Retinal ischemia-induced apoptosis is associated with alteration in Bax and Bcl-x(L) expression rather than modifications in Bak and Bcl-2. Mol. Vis. 2009, 15:2101-2110.
22. Santini V., Gozzini A., et al. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr. Drug Metab. 2007, 8(4):383-393.
23. Schwechter B.R., Millet L.E., et al. Histone deacetylase inhibition-mediated differentiation of RGC-5 cells and interaction with survival. Investig. Ophthalmol. Vis. Sci. 2007, 48(6):2845-2857.
24. Sinn D.I., Kim S.J., et al. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol. Dis. 2007, 26(2):464-472.
25. Walkinshaw D.R., Tahmasebi S., et al. Histone deacetylases as transducers and targets of nuclear signaling. J.Cell. Biochem. 2008, 104(5):1541-1552.
26. Wallace D.M., Donovan M., et al. Histone deacetylase activity regulates apaf-1 and caspase 3 expression in the developing mouse retina. Investig. Ophthalmol. Vis. Sci. 2006, 47(7):2765-2772.
27. Wegener D., Hildmann C., et al. Improved fluorogenic histone deacetylase assay for high-throughput-screening applications. Anal. Biochem. 2003, 321(2):202-208.
28. Whitlock N.A., Agarwal N., et al. Hsp27 upregulation by HIF-1 signaling offers protection against retinal ischemia in rats. Investig. Ophthalmol. Vis. Sci. 2005, 46(3):1092-1098.
29. Whyte W.A., Bilodeau S., et al. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature 2012, 482(7384):221-225.
30. Yang W.M., Tsai S.C., et al. Functional domains of histone deacetylase-3. J.Biol. Chem. 2002, 277(11):9447-9454.
31. Zhang C.L., McKinsey T.A., et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002, 110(4):479-488.
32. Zhang Z.K., Davies K.P., et al. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol. Cell. Biol. 2002, 22(16):5975-5988.
33. Zhong Q., Kowluru R.A. Role of histone acetylation in the development of diabetic retinopathy and the metabolic memory phenomenon. J.Cell. Biochem. 2010, 110(6):1306-1313.